Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PLX-PAD · 4 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| PLX-PAD | EXPERIMENTAL | • Arm 1 - PLX-PAD (120 subjects): 150×10\^6 PLX-PAD cells (10×10\^6 cells/mL) in a mixture containing 10% DMSO (v/v), 5% HSA (w/v) and PlasmaLyte. |
| Placebo | PLACEBO_COMPARATOR | Arm 2 Placebo (120 subjects): Placebo (solution comprised of 10% DMSO \[v/v\], 5% HSA \[w/v\], and PlasmaLyte, without cells). |
| PLX-PAD low dose | EXPERIMENTAL | IM injection Single treatment; multiple injections |
| PLX-PAD high dose | EXPERIMENTAL | IM injection Double treatment; multiple injections |
| PLX-PAD intermediate dose | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PLX-PAD | DRUG | PLX-PAD (120 subjects): 150×10\^6 PLX-PAD cells (10×10\^6 cells/mL) in a mixture containing 10% DMSO (v/v), 5% HSA (w/v) and PlasmaLyte |
| Placebo | DRUG | Arm 2 Placebo (120 subjects): Placebo (solution comprised of 10% DMSO \[v/v\], 5% HSA \[w/v\], and PlasmaLyte, without cells). |
| PLX-PAD IM injection | BIOLOGICAL | Single treatment; multiple injections |
Inclusion Criteria: 1. Male or female subjects 2. Subjects up to 90 years of age, inclusive, at the time of Screening 3. Subjects suffering low energy trauma with intracapsular neck of femur fracture. 4. Planned to be treated with total hip arthroplasty (THA) or hemi-arthroplasty (HA) within 48 hou...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. | ZBH | 23 | N/A | Undisclosed |
| Stryker Corporation | SYK | 4 | - | Undisclosed |
| Johnson & Johnson | JNJ | 1 | N/A | Undisclosed |
| Orthofix Medical, Inc. | OFIX | 1 | - | Undisclosed |
| Cooper Companies, Inc. | COO | 1 | - | Undisclosed |